Cargando…

Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study

BACKGROUND/AIMS: Proton pump inhibitors (PPIs) which are the most effective agents for the treatment of gastroesophageal reflux disease (GERD), have been known to delay gastric emptying. Mosapride has been used as prokinetics by accelerating gastric emptying. We evaluated the efficacy of mosapride t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Hyun Chul, Kim, Jie-Hyun, Youn, Young Hoon, Lee, Eun Hee, Lee, Byung Keon, Park, Hyojin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Neurogastroenterology and Motility 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816184/
https://www.ncbi.nlm.nih.gov/pubmed/24199010
http://dx.doi.org/10.5056/jnm.2013.19.4.495
_version_ 1782477925147213824
author Lim, Hyun Chul
Kim, Jie-Hyun
Youn, Young Hoon
Lee, Eun Hee
Lee, Byung Keon
Park, Hyojin
author_facet Lim, Hyun Chul
Kim, Jie-Hyun
Youn, Young Hoon
Lee, Eun Hee
Lee, Byung Keon
Park, Hyojin
author_sort Lim, Hyun Chul
collection PubMed
description BACKGROUND/AIMS: Proton pump inhibitors (PPIs) which are the most effective agents for the treatment of gastroesophageal reflux disease (GERD), have been known to delay gastric emptying. Mosapride has been used as prokinetics by accelerating gastric emptying. We evaluated the efficacy of mosapride to prevent PPI-induced delayed gastric emptying in a prospective randomized, double-blind and placebo-controlled trial. METHODS: Thirty patients who were diagnosed as GERD and had normal gastric emptying were included in this study. PPI monotherapy group was treated with placebo drug in addition to pantoprazole and PPI plus mosapride group was treated with mosapride in addition to pantoprazole for 8 weeks. Gastric emptying scan and questionnaires about GERD and dyspeptic symptoms were assessed by scoring before and after treatment. To evaluate the changes of gastrointestinal endocrine hormones by PPI which are associated gastric acid secretion and gastric motility, fasting plasma gastrin and cholecystokinin were taken at weeks 0 and 8. RESULTS: Half gastric emptying time was increased (P = 0.023) in PPI monotherapy group, and there were no significant changes in PPI plus mosapride group. Plasma gastrin level increased in PPI monotherpay group (P = 0.028) and there were no significant changes in PPI plus mosapride group. Plasma cholecystokinin level was not changed after treatment in both groups. GERD symptoms were improved after treatment in both groups, and postprandial bloating and nausea were improved in PPI plus mosapride group. CONCLUSIONS: Mosapride showed to be effective in preventing delayed gastric emptying and the increase in plasma gastrin level induced by PPI treatment, but did not show prominent clinical symptom improvements.
format Online
Article
Text
id pubmed-3816184
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Korean Society of Neurogastroenterology and Motility
record_format MEDLINE/PubMed
spelling pubmed-38161842013-11-06 Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study Lim, Hyun Chul Kim, Jie-Hyun Youn, Young Hoon Lee, Eun Hee Lee, Byung Keon Park, Hyojin J Neurogastroenterol Motil Original Article BACKGROUND/AIMS: Proton pump inhibitors (PPIs) which are the most effective agents for the treatment of gastroesophageal reflux disease (GERD), have been known to delay gastric emptying. Mosapride has been used as prokinetics by accelerating gastric emptying. We evaluated the efficacy of mosapride to prevent PPI-induced delayed gastric emptying in a prospective randomized, double-blind and placebo-controlled trial. METHODS: Thirty patients who were diagnosed as GERD and had normal gastric emptying were included in this study. PPI monotherapy group was treated with placebo drug in addition to pantoprazole and PPI plus mosapride group was treated with mosapride in addition to pantoprazole for 8 weeks. Gastric emptying scan and questionnaires about GERD and dyspeptic symptoms were assessed by scoring before and after treatment. To evaluate the changes of gastrointestinal endocrine hormones by PPI which are associated gastric acid secretion and gastric motility, fasting plasma gastrin and cholecystokinin were taken at weeks 0 and 8. RESULTS: Half gastric emptying time was increased (P = 0.023) in PPI monotherapy group, and there were no significant changes in PPI plus mosapride group. Plasma gastrin level increased in PPI monotherpay group (P = 0.028) and there were no significant changes in PPI plus mosapride group. Plasma cholecystokinin level was not changed after treatment in both groups. GERD symptoms were improved after treatment in both groups, and postprandial bloating and nausea were improved in PPI plus mosapride group. CONCLUSIONS: Mosapride showed to be effective in preventing delayed gastric emptying and the increase in plasma gastrin level induced by PPI treatment, but did not show prominent clinical symptom improvements. Korean Society of Neurogastroenterology and Motility 2013-10 2013-10-07 /pmc/articles/PMC3816184/ /pubmed/24199010 http://dx.doi.org/10.5056/jnm.2013.19.4.495 Text en © 2013 The Korean Society of Neurogastroenterology and Motility http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lim, Hyun Chul
Kim, Jie-Hyun
Youn, Young Hoon
Lee, Eun Hee
Lee, Byung Keon
Park, Hyojin
Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study
title Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study
title_full Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study
title_fullStr Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study
title_full_unstemmed Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study
title_short Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study
title_sort effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor: a prospective randomized, double-blind study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816184/
https://www.ncbi.nlm.nih.gov/pubmed/24199010
http://dx.doi.org/10.5056/jnm.2013.19.4.495
work_keys_str_mv AT limhyunchul effectsoftheadditionofmosapridetogastroesophagealrefluxdiseasepatientsonprotonpumpinhibitoraprospectiverandomizeddoubleblindstudy
AT kimjiehyun effectsoftheadditionofmosapridetogastroesophagealrefluxdiseasepatientsonprotonpumpinhibitoraprospectiverandomizeddoubleblindstudy
AT younyounghoon effectsoftheadditionofmosapridetogastroesophagealrefluxdiseasepatientsonprotonpumpinhibitoraprospectiverandomizeddoubleblindstudy
AT leeeunhee effectsoftheadditionofmosapridetogastroesophagealrefluxdiseasepatientsonprotonpumpinhibitoraprospectiverandomizeddoubleblindstudy
AT leebyungkeon effectsoftheadditionofmosapridetogastroesophagealrefluxdiseasepatientsonprotonpumpinhibitoraprospectiverandomizeddoubleblindstudy
AT parkhyojin effectsoftheadditionofmosapridetogastroesophagealrefluxdiseasepatientsonprotonpumpinhibitoraprospectiverandomizeddoubleblindstudy